Tropane alkaloids (TAs) are naturally occurring compounds that play significant roles in pharmacology and medicinal chemistry. These alkaloids are derived from various plants, particularly those in the Solanaceae family, such as belladonna and henbane. Their unique chemical structure, characterized by a bicyclic tropane ring, contributes to their diverse pharmacological effects, including anticholinergic and central nervous system activities. Biosimilars-biopharmaceuticals’ development has emerged as a significant trend in the pharmaceutical industry. While most biosimilars focus on protein-based drugs, the principles can extend to alkaloids, particularly in establishing equivalence in efficacy and safety. The regulatory frameworks for biosimilars encourage the development of alternative formulations of existing drugs, potentially offering more affordable options for patients. Biosimilars have great potential to improve patient care by reducing costs and making access to biological treatments easier. They will handle questions from patients and other healthcare providers about biosimilars and ensure they are effectively integrated into medical practice. The biosynthesis of TAs (TAs biosimilars) involves a series of enzymatic reactions that convert simple amino acids into complex alkaloid structures. The pathway typically begins with the amino acid ornithine, which is transformed into putrescine. Enzymatic modifications lead to the formation of tropin and, eventually, tropane derivatives. Biosynthetic TAs have a wide range of pharmacological applications. Biosynthesized atropine is commonly used clinically as an antimuscarinic agent to treat bradycardia, reduce salivation during surgery, and counteract organophosphate poisoning. Biosynthesized scopolamine, another prominent tropane alkaloid biosimilar, is primarily used for its antiemetic properties, particularly in motion sickness, antidepressant, and postoperative nausea. The effectiveness of these compounds stems from their ability to inhibit the action of acetylcholine at muscarinic receptors. The field of biopharmaceutics is rapidly evolving, focusing on improving the efficacy and safety of drug delivery systems. TA biosimilars present unique challenges and opportunities in this context. Their lipophilic nature allows for easy penetration through biological membranes, which can also lead to variable absorption rates and bioavailability.